Rockefeller Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-6,247
| Closed | -$249K | – | 1983 |
|
|
2023
Q1 | $249K | Sell |
6,247
-1,949
| -24% | -$77.7K | ﹤0.01% | 1693 |
|
|
2022
Q4 | $379K | Buy |
8,196
+1,360
| +20% | +$62.9K | ﹤0.01% | 1380 |
|
|
2022
Q3 | $282K | Buy |
6,836
+3,364
| +97% | +$139K | ﹤0.01% | 1496 |
|
|
2022
Q2 | $206K | Buy |
3,472
+58
| +2% | +$3.44K | ﹤0.01% | 1627 |
|
|
2022
Q1 | $247K | Sell |
3,414
-68
| -2% | -$4.92K | ﹤0.01% | 1604 |
|
|
2021
Q4 | $292K | Buy |
3,482
+1,965
| +130% | +$165K | ﹤0.01% | 1513 |
|
|
2021
Q3 | $136K | Sell |
1,517
-54
| -3% | -$4.84K | ﹤0.01% | 1734 |
|
|
2021
Q2 | $149K | Buy |
1,571
+58
| +4% | +$5.5K | ﹤0.01% | 1638 |
|
|
2021
Q1 | $172K | Sell |
1,513
-2,541
| -63% | -$289K | ﹤0.01% | 1377 |
|
|
2020
Q4 | $560K | Buy |
4,054
+1,885
| +87% | +$260K | ﹤0.01% | 875 |
|
|
2020
Q3 | $177K | Buy |
2,169
+55
| +3% | +$4.49K | ﹤0.01% | 1076 |
|
|
2020
Q2 | $165K | Hold |
2,114
| – | – | ﹤0.01% | 1010 |
|
|
2020
Q1 | $94K | Sell |
2,114
-463
| -18% | -$20.6K | ﹤0.01% | 1031 |
|
|
2019
Q4 | $110K | Sell |
2,577
-160
| -6% | -$6.83K | ﹤0.01% | 938 |
|
|
2019
Q3 | $117K | Sell |
2,737
-66
| -2% | -$2.82K | ﹤0.01% | 750 |
|
|
2019
Q2 | $178K | Buy |
2,803
+562
| +25% | +$35.7K | ﹤0.01% | 594 |
|
|
2019
Q1 | $156K | Buy |
2,241
+125
| +6% | +$8.7K | ﹤0.01% | 656 |
|
|
2018
Q4 | $92K | Hold |
2,116
| – | – | ﹤0.01% | 466 |
|
|
2018
Q3 | $162K | Hold |
2,116
| – | – | ﹤0.01% | 366 |
|
|
2018
Q2 | $163K | Hold |
2,116
| – | – | ﹤0.01% | 344 |
|
|
2018
Q1 | $108K | Buy |
+2,116
| New | +$108K | ﹤0.01% | 367 |
|